End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
5-day change
1st Jan Change
65,700
KRW
-1.20%
-4.23%
+1.08%
This article is reserved for members
Not a member ?
Free registration
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024
04-08
CI
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.
03-28
CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-21
CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing
02-09
MT
Orion Set to Acquire 25% Stake in LegoChem Biosciences
01-17
MT
South Korean Shares Close Lower Amid Geopolitical Tension
01-16
MT
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%
01-15
MT
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.
01-14
CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.
12-27
CI
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.
12-27
CI
J&J: licensing agreement with Korea's LegoChem in ADCs
12-27
CF
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC
12-25
CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers
11-07
CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.
23-10-04
CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.
23-10-04
CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.
23-09-04
CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.
23-08-27
CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-11
CI
LegoChem Biosciences, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.
23-06-28
CI
LegoChem Biosciences, Inc. authorizes a Buyback Plan.
23-06-27
CI
LegoChem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-23
CI
LegoChem Biosciences, Amgen in Licensing Agreement
22-12-23
DJ
Legochem Biosciences and Amgen Enter into A Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
22-12-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based biotechnology company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells pharmaceutical products.
More about the company
1st Jan change
Capi.
+1.08% 1.75B +7.52% 113B +11.38% 106B +0.58% 22.27B -12.64% 22.22B -3.99% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**